Torrent Pharma expands recall of Losartan tablets in US over carcinogen impurity
"The recall is expanded to include an additional three lots of Losartan potassium tablets USP and 2 lots of Losartan potassium/hydrochlorothiazide tablets, USP," Torrent Pharma added.
New Delhi: Drug firm Torrent Pharmaceuticals is expanding its voluntary recall for tablets used to control hypertension in the US due to detection of traces of N-Methylnitrosobutyric acid, according to health regulator USFDA.
The company is expanding recall for Losartan potassium tablets USP and Losartan potassium/hydrochlorothiazide tablets to the consumer level due to the detection of trace amounts of an unexpected impurity while testing some finished product batches manufactured utilising active pharmaceutical ingredient manufactured by Hetero Labs, Torrent Pharmaceuticals said in an announcement posted on the website of USFDA.
"The recall is expanded to include an additional three lots of Losartan potassium tablets USP and 2 lots of Losartan potassium/hydrochlorothiazide tablets, USP," it added.
The impurity detected is N-Methylnitrosobutyric acid (NMBA), the statement said.
Torrent is only recalling lots of losartan-containing products that contain N-Methylnitrosobutyric acid (NMBA) above the acceptable daily intake levels released by the FDA, it added.
According to the regulator, the impurity is a known animal and potential human carcinogen.
"Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Losartan Potassium and Hydrochlorothiazide tablets, USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy," it added.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here